Myriad Genetics (MYGN) shares were down more than 4% in recent trading Thursday after Wolfe Research downgraded the company to peer perform from outperform.
Trading volume stood at over 3.7 million shares against a daily average of about 1.6 million shares.
Price: 4.09, Change: -0.19, Percent Change: -4.33